Novo touts CagriSema's win over semaglutide in pivotal diabetes study FirstWord Pharma Cagrilintide (AM833) Long acting amylin analog. Beta cells make TWO hormones: insulin and amylin. Amylin slows stomach emptying and reduces appetite. Cagrilintide is a long acting synthetic amylin designed for once weekly dosing Latest science on Cagrilintide from Novo Nordisk Novo Nordisk's next gen obesity drug CagriSema trial results disappoint investors TrimRX Novo Nordisk submits application for FDA approval of CagriSema for weight management Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination